Current Report Filing (8-k)
March 23 2021 - 10:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): March 23, 2021
ANNOVIS
BIO, INC.
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
001-39202
|
|
26-2540421
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
(Address of Principal Executive Offices,
and Zip Code)
(610) 727-3913
Registrant’s Telephone Number,
Including Area Code
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common Stock, par value $0.0001 per
share
|
ANVS
|
NYSE American
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communication pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
|
Item 7.01
|
Regulation FD Disclosure.
|
On March 24, 2021, as part of the Q1 Investor Summit,
Chief Executive Officer Maria Maccecchini, Ph.D., and Chief Financial Officer Jeff McGroarty, MBA, CPA, will give a presentation
via webcast at 11:30 a.m. Eastern Time, followed by a live Q&A session. A copy of the written presentation materials is attached
as Exhibit 99.1 to this Current Report on Form 8-K. A copy of the presentation is also available on the Company’s website
at www.annovisbio.com under “Investors & Media.” Investors can register for and access the live webcast at: https://zoom.us/webinar/register/WN_LKCiDrrKROa4nLfrPKSiAA
The information in this Item 7.01, including
the attached exhibit, is furnished solely pursuant to Item 7.01 of Form 8-K. Consequently, such information is not deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Further,
the information in this Item 7.01, including the exhibit, shall not be deemed to be incorporated by reference into the filings
of the registrant under the Securities Act of 1933.
Cautionary Statement Regarding Forward-Looking
Information
This current report on Form 8-K contains
“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements
other than those of historical fact in this presentation and accompanying oral commentary are forward-looking statements. Forward-looking
statements may be identified by terminology such as “believe,” “anticipate,” “plan,” “may,”
“intend,” “will,” “should,” “expect,” “estimate,” “potential”
and “continue” and similar expressions, including the negative of these words, but not all forward-looking statements
contain these words. Forward-looking statements include, but are not limited to, statements regarding the Company’s expectations
regarding projected timelines of clinical trials, and expectations regarding current or future clinical trials. Forward-looking
statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions
that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may
not prove to be accurate, including the timing of clinical trials. These and other risks and uncertainties are described more fully
in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with
the Securities and Exchange Commission (“SEC”) and elsewhere in our filings and reports with the SEC. These risks,
uncertainties and other factors may cause our actual results to differ materially and adversely from what is contained in (or may
be implied from) any forward-looking statements. Forward-looking statements speak as of the date they are made, and the Company
undertakes no obligation to update them except as may be required under applicable law.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ANNOVIS BIO, INC.
|
|
|
|
Date: March 23, 2021
|
By:
|
/s/ Jeffrey McGroarty
|
|
|
Name: Jeffrey McGroarty
|
|
|
Title: Chief Financial Officer
|
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2023 to Apr 2024